Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial

被引：72

作者：

Makawita, Shalini ^{[1
]}

Abou-Alfa, Ghassan K. ^{[2
,3
]}

Roychowdhury, Sameek ^{[4
,5
]}

Sadeghi, Saeed ^{[6
]}

Borbath, Ivan ^{[7
,8
]}

Goyal, Lipika ^{[9
,10
]}

Cohn, Allen ^{[11
,12
]}

Lamarca, Angela ^{[13
]}

Oh, Do-Youn ^{[14
]}

Macarulla, Teresa ^{[15
]}

Shroff, Rachna T. ^{[16
]}

Howland, Michael ^{[17
]}

Li, Ai ^{[17
]}

Cho, Terry ^{[17
]}

Pande, Amit ^{[17
]}

Javle, Milind ^{[1
,18
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA

[3] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA

[4] Ohio State Univ, Dept Internal Med, Div Med Oncol, James Canc Hosp, Columbus, OH 43210 USA

[5] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA

[6] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90404 USA

[7] Clin Univ St Luc, Dept Gastroenterol & Digest Oncol, Brussels, Belgium

[8] Catholic Univ Louvain, Brussels, Belgium

[9] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[10] Harvard Med Sch, Dept Med, Boston, MA 02115 USA

[11] Rocky Mt Canc Ctr, Denver, CO 80218 USA

[12] US Oncol Res, Denver, CO 80218 USA

[13] Univ Manchester, Div Canc Sci, Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England

[14] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[15] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol & IOB quiron, Barcelona, Spain

[16] Univ Arizona, Ctr Canc, Div Hematol Oncol, Tucson, AZ 85724 USA

[17] QED Therapeut, San Francisco, CA USA

[18] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA

来源：

FUTURE ONCOLOGY | 2020年 / 16卷 / 30期

关键词：

cholangiocarcinoma; fibroblast growth factor receptor inhibitor; infigratinib; targeted therapy; CANCER; INHIBITOR; BGJ398; TARGET;

D O I：

10.2217/fon-2020-0299

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cholangiocarcinoma is an aggressive malignancy with poor overall survival. Approximately 15% of intrahepatic cholangiocarcinomas contain FGFR alterations. Infigratinib is an oral FGFR 1-3 kinase inhibitor. Favorable results from a Phase II trial of infigratinib in advanced/metastatic FGFR-altered cholangiocarcinomas has led to its further investigation in the front-line setting. In this article we describe the design, objectives and rationale for PROOF 301, a Phase III multicenter, open label, randomized trial of infigratinib in comparison to standard of care gemcitabine and cisplatin in advanced/metastatic cholangiocarcinoma with FGFR2 translocations. The results of this study have the potential to define a new role for a chemotherapy-free, targeted therapy option in the front-line setting for these patients.

引用

页码：2375 / 2384

页数：10

共 50 条

[31] Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
Neumann, Olaf
Burn, Timothy C.
Allgaeuer, Michael
Ball, Markus
Kirchner, Martina
Albrecht, Thomas
Volckmar, Anna-Lena
Beck, Susanne
Endris, Volker
Goldschmid, Hannah
Lehmann, Ulrich
Seker-Cin, Huriye
Uhrig, Sebastian
Roessler, Stephanie
Budczies, Jan
Froehling, Stefan
Longerich, Thomas
Wagner, Alex H.
Vogel, Arndt
Schirmacher, Peter
Stenzinger, Albrecht
Kazdal, Daniel
BRITISH JOURNAL OF CANCER, 2022, 127 (08) : 1540 - 1549
[32] Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing
Olaf Neumann
Timothy C. Burn
Michael Allgäuer
Markus Ball
Martina Kirchner
Thomas Albrecht
Anna-Lena Volckmar
Susanne Beck
Volker Endris
Hannah Goldschmid
Ulrich Lehmann
Huriye Seker-Cin
Sebastian Uhrig
Stephanie Roessler
Jan Budczies
Stefan Fröhling
Thomas Longerich
Alex H. Wagner
Arndt Vogel
Peter Schirmacher
Albrecht Stenzinger
Daniel Kazdal
British Journal of Cancer, 2022, 127 : 1540 - 1549
[33] Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma
Kongpetch, Sarinya
Jusakul, Apinya
Lim, Jing Quan
Ng, Cedric Chuan Young
Chan, Jason Yongsheng
Rajasegaran, Vikneswari
Lim, Tse Hui
Lim, Kiat Hon
Choo, Su Pin
Dima, Simona
Popescu, Irinel
Duda, Dan G.
Kukongviriyapan, Veerapol
Khuntikeo, Narong
Pairojkul, Chawalit
Rozen, Steven G.
Tan, Patrick
Teh, Bin Tean
JCO GLOBAL ONCOLOGY, 2020, 6 : 628 - 638
[34] Clinical outcomes and genomic evolution of FGFR2 fusions/rearrangements in intrahepatic cholangiocarcinoma
Cham, Brent B.
Lee, Sunyoung S.
CANCER RESEARCH, 2022, 82 (12)
[35] Targeting FGFR2 in advanced cholangiocarcinoma: an interview with Arndt Vogel
Vogel, Arndt
FUTURE ONCOLOGY, 2020, 16 (30) : 2373 - 2374
[36] A phase 2 study of HMPL-453, a selective FGFR tyrosine kinase inhibitor (TKI), in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
Xu, Jianming
Xiong, Jianping
Gu, Shanzhi
Niu, Zuoxing
Yin, Fei
Sun, Beicheng
Zhang, Lan
Zhou, Fuxiang
Hao, Chunyi
Pan, Yueyin
Qiu, Wensheng
Gao, Yi
Ren, Yongxin
Fan, Songhua
Shi, Michael
Su, Weiguo
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[37] A retrospective analysis of post second-line chemotherapy treatment outcomes for patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions.
Javle, Milind M.
Sadeghi, Saeed
El-Khoueiry, Anthony B.
Goyal, Lipika
Philip, Philip Agop
Kelley, Robin Kate
Borbath, Ivan
Macarulla, Teresa
Yong, Wei-Peng
Tanasanvimon, Suebpong
Pande, Amit
Li, Gary
Howland, Michael
Berman, Craig
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[38] Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study
Shi, Guo-Ming
Huang, Xiao-Yong
Wen, Tian-Fu
Song, Tian-Qiang
Kuang, Ming
Mou, Hai-Bo
Bao, Le-Qun
Zhao, Hai-Tao
Zhao, Hong
Feng, Xie-Lin
Zhang, Bi-Xiang
Peng, Tao
Zhang, Yu-Bao
Li, Xiang-Cheng
Yu, Hong-Sheng
Cao, Yu
Liu, Lian-Xin
Zhang, Ti
Wang, Wei-Lin
Ran, Jiang-Hua
Liu, Ying-Bin
Gong, Wei
Chen, Ming-Xia
Cao, Lian
Luo, Yang
Wang, Yan
Zhou, Hui
Yang, Guo-Huan
Fan, Jia
Zhou, Jian
CANCER MEDICINE, 2023, 12 (04): : 4137 - 4146
[39] FGFR2 fusion in resectable intrahepatic cholangiocarcinoma patients
Xu, S.
Zheng, Y.
Gong, W.
Li, B.
Wang, Y.
Li, H.
Zhao, S.
Shi, X.
Zhang, L.
ANNALS OF ONCOLOGY, 2020, 31 : S267 - S267
[40] Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Javle, Milind
Roychowdhury, Sameek
Kelley, Robin Kate
Sadeghi, Saeed
Macarulla, Teresa
Weiss, Karl Heinz
Waldschmidt, Dirk-Thomas
Goyal, Lipika
Borbath, Ivan
El-Khoueiry, Anthony
Borad, Mitesh J.
Yong, Wei Peng
Philip, Philip A.
Bitzer, Michael
Tanasanvimon, Surbpong
Li, Ai
Pande, Amit
Soifer, Harris S.
Shepherd, Stacie Peacock
Moran, Susan
Zhu, Andrew X.
Bekaii-Saab, Tanios S.
Abou-Alfa, Ghassan K.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (10): : 803 - 815

← 1 2 3 4 5 →